Here are four things to know regarding the development:
- Johnson & Johnson’s announced its new policy in a letter sent to hospitals Aug. 23. It will eliminate upfront rebates for drugs purchased by hospitals participating in the 340B drug pricing program, designed to help safety-net providers by offering discounted medications.
- The Health Resources and Services Administration issued a warning to Johnson & Johnson about its rebate plan, emphasizing the potential violations of federal law. The agency also raised concerns that the move could limit access to affordable medications for vulnerable populations.
- Pharmacy organizations strongly criticized the drugmaker’s decision, arguing that the removal of upfront rebates could exacerbate financial pressures on hospitals, ultimately affecting patient care.
- Johnson & Johnson said it will work with stakeholders to address concerns, but the timeline for implementation remains unclear.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
